Skip to main content
. Author manuscript; available in PMC: 2015 Sep 28.
Published in final edited form as: J Control Release. 2014 Jun 28;190:314–330. doi: 10.1016/j.jconrel.2014.06.028

Table 2.

Hyperthermia-targeted drug carriers

Application ELP sequence Pertinent functionalization Ref
Tumor-targeted unimer aggregation Temperature-sensitive ELP: (VPGXG)150* X=V5G3A2 and Temperature-insensitive ELP: (VPGXG)160 X=V1G7A8 Lysine residue for rhodamine conjugation and visualization of tumor accumulation in vivo [74, 75]
14C labeling for autoradiography of tumor accumulation in vivo [26]
Lysine residue for Alexa Fluor 488/Alexa Fluor 546 conjugation and visualization of tumor accumulation by thermal cycling in vivo [76]
Lysine residue for fluorescein conjugation and quantification of intracellular uptake in vitro [77]
Penetratin CPP for enhanced intracellular delivery of H1 peptide drug [79]
Bac CPP for enhanced intracellular delivery of H1 (*n=130 for in vitro applications [80]) or p21 peptide drug [80, 81, 85, 86]
TAT CPP for enhanced intracellular delivery of L12 peptide drug [82]
SynB1 CPP for enhanced intracellular delivery of GRG peptide drug [83]
TAT CPP for enhanced intracellular delivery of doxorubicin conjugated to cysteine residue with enzyme-cleavable peptide linker [46, 87]
SynB1 CPP for enhanced intracellular delivery of paclitaxel or doxorubicin conjugated to cysteine residue(s) with acid-cleavable hydrazone linker [88–90]
Tumor-targeted unimer-to-micelle transition (VPGXG)96 [X=V1A8G7]-(VPGVG)60 NGR at hydrophilic terminus for temperature-triggered multivalent targeting of CD13 receptor [47]
(VPGXG)64 [X=V1A8G7]-(VPGVG)90 RGD at hydrophilic terminus for temperature-triggered multivalent targeting of αvβ3 integrin [91]
(VPGXG)96 [X=V1A8G7]-(VPGVG)90 Fn3 at hydrophilic terminus for temperature-triggered multivalent targeting of αvβ3 integrin [92]
(VPGVG)40-(VPGXG)60 X=A1G1 Arg5 or Arg8 CPP at hydrophilic terminus for temperature-triggered non-specific cellular uptake and controlled delivery of pro-apoptotic BH3 peptide drug [93, 94]
Tumor-targeted micelle aggregation (VPGXG)150 or 160 X=AaVb where a:b=1:0, 14:1, 9:1, or 4:1 C(GGC)7 for conjugation of doxorubicin with acid-cleavable hydrazone linker [95]